Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 490295, 9 pages
http://dx.doi.org/10.1155/2015/490295
Research Article

TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy

1Rheumatology Research Unit, Instituto de Medicina Molecular, Edifício Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Avenida Egas Moniz, 1649-028 Lisbon, Portugal
2Rheumatology Department, Hospital de Santa Maria (CHLN), Lisbon Academic Medical Centre, 1649-035 Lisbon, Portugal
3Division of Rheumatology, Allergy and Immunology, Section of Clinical Sciences, Brigham and Women’s Hospital, Boston, MA 02115, USA
4Rheumatology Department, Hospital Garcia de Orta, 2805-267 Almada, Portugal
5SEEBMO, Hospital de Santo Espirito da Ilha Terceira, Azores, 9700-049 Angra do Heroísmo, Portugal
6Genetics & Arthritis Research Group (GARG), Institute for Molecular and Cell Biology (IBMC), 4150-180 Oporto, Portugal
7Rheumatology Department, Conde de Bertiandos Hospital (ULSAM), 4990-041 Ponte de Lima, Portugal
8Instituto Português de Reumatologia, Lisbon, Portugal
9Rheumatology Department, Centro Hospitalar da Universidade de Coimbra, 3000-076 Coimbra, Portugal
10Rheumatology Department, Virgen de las Nieves University Hospital, Granada, Spain
11Rheumatology Department, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
12CEDOC, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
13Rheumatology Department, Hospital de Egas Moniz (CHLO), 1349-019 Lisbon, Portugal
14Genomic Oncology Area, GENYO Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain
15The Broad Institute of Harvard and MIT, Cambridge, MA, USA
16Division of Pharmacoepidemiology, Brigham and Women’s Hospital, Boston, MA, USA

Received 25 July 2014; Accepted 26 November 2014

Academic Editor: María E. Esteban

Copyright © 2015 Helena Canhão et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. C. Taylor and M. Feldmann, “Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 5, no. 10, pp. 578–582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Maini, E. W. St Clair, F. Breedveld et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial,” The Lancet, vol. 354, no. 9194, pp. 1932–1939, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. L. Hetland, I. J. Christensen, U. Tarp et al., “Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 22–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. K. L. Hyrich, K. D. Watson, A. J. Silman, and D. P. M. Symmons, “Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register,” Rheumatology, vol. 45, no. 12, pp. 1558–1565, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Canhão, A. M. Rodrigues, A. F. Mourão et al., “Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis,” Rheumatology, vol. 51, no. 11, pp. 2020–2026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Mancarella, F. Bobbio-Pallavicini, F. Ceccarelli et al., “Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: the GISEA study,” The Journal of Rheumatology, vol. 34, no. 8, pp. 1670–1673, 2007. View at Google Scholar
  8. D. Ligeiro, J. E. Fonseca, O. Abade et al., “Influence of human leucocyte antigen-DRB1 on the susceptibility to rheumatoid arthritis and on the production of anti-cyclic citrullinated peptide antibodies in a Portuguese population,” Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 246–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Barnetche, A. Constantin, A. Cantagrel, A. Cambon-Thomsen, and P.-A. Gourraud, “New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples,” Arthritis Research and Therapy, vol. 10, article R26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. W. Morgan, J. I. Robinson, P. G. Conaghan et al., “Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort,” Arthritis Research and Therapy, vol. 12, no. 2, article R57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. B. Van Nies, R. B. Marques, S. Trompet et al., “TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies,” Arthritis Research and Therapy, vol. 12, no. 2, article R38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. V. F. Panoulas, J. P. Smith, P. Nightingale, and G. D. Kitas, “Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 60, no. 1, pp. 39–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. O'Dell, B. S. Nepom, C. Haire et al., “HLA-DRB1 typing in rheumatoid arthritis: Predicting response to specific treatments,” Annals of the Rheumatic Diseases, vol. 57, no. 4, pp. 209–213, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Saruhan-Direskeneli, M. Inanc, I. Fresko et al., “The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis,” Rheumatology, vol. 46, no. 12, pp. 1842–1844, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. A. Criswell, R. F. Lum, K. N. Turner et al., “The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept,” Arthritis & Rheumatism, vol. 50, no. 9, pp. 2750–2756, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Martinez, M. Salido, G. Bonilla et al., “Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients,” Arthritis and Rheumatism, vol. 50, no. 4, pp. 1077–1082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. E. Fonseca, T. Carvalho, M. Cruz et al., “Polymorphism at position −308 of the tumour factor α gene and rheumatoid arthritis pharmacogenetics,” Annals of the Rheumatic Diseases, vol. 64, no. 5, pp. 793–794, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Pavy, E. J. M. Toonen, C. Miceli-Richard et al., “Tumour necrosis factor α-308GA polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1022–1028, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fabris, E. Di Poi, S. Sacco, G. Damante, L. Sinigaglia, and G. Ferraccioli, “TNF-α gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-α agents: preliminary results,” Reumatismo, vol. 54, no. 1, pp. 19–26, 2002. View at Google Scholar · View at Scopus
  20. L. Padyukov, J. Lampa, M. Heimbürger et al., “Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 6, pp. 526–529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. R. M. Plenge, M. Seielstad, L. Padyukov et al., “TRAF1-C5 as a risk locus for rheumatoid arthritis—a genomewide study,” The New England Journal of Medicine, vol. 357, no. 12, pp. 1199–1209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Stahl, S. Raychaudhuri, E. F. Remmers et al., “Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci,” Nature Genetics, vol. 42, pp. 509–514, 2010. View at Google Scholar
  23. P. R. Burton, D. G. Clayton, L. R. Cardon et al., “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls,” Nature, vol. 447, no. 7145, pp. 661–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Plenge, L. Padyukov, E. F. Remmers et al., “Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4,” The American Journal of Human Genetics, vol. 77, no. 6, pp. 1044–1060, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Barton, W. Thomson, X. Ke et al., “Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility,” Human Molecular Genetics, vol. 17, no. 15, pp. 2274–2279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Thomson, A. Barton, X. Ke et al., “Rheumatoid arthritis association at 6q23,” Nature Genetics, vol. 39, no. 12, pp. 1431–1433, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Snir, D. Gomez-Cabrero, A. Montes et al., “Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis,” Arthritis Research & Therapy, vol. 16, no. 5, article 414, 2014. View at Google Scholar
  28. J. Varadé, R. Palomino-Morales, N. Ortego-Centeno et al., “Analysis of the rel polymorphism rs13031237 in autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 711–712, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Cui, S. Saevarsdottir, B. Thomson et al., “Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor α therapy,” Arthritis & Rheumatism, vol. 62, no. 7, pp. 1849–1861, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Potter, K. L. Hyrich, A. Tracey et al., “Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 69–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Plant, R. Prajapati, K. L. Hyrich et al., “Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort,” Arthritis and Rheumatism, vol. 64, no. 3, pp. 665–670, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Canhão, A. Faustino, F. Martins et al., “Reuma.pt: the rheumatic diseases portuguese register,” Acta Reumatologica Portuguesa, vol. 36, pp. 45–56, 2011. View at Google Scholar
  33. Biobanco-IMM, http://www.imm.fm.ul.pt/web/imm/biobank.
  34. J. E. Fonseca, M. Bernardes, H. Canhão et al., “Portuguese guide lines for the use of biological agents in rheumatoid arthritis—october 2011 update,” Acta Reumatologica Portuguesa, vol. 36, no. 4, pp. 385–388, 2011. View at Google Scholar · View at Scopus
  35. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  36. DAS 28 calculator, /http://www.das-score.nl/das28/en.
  37. A. M. van Gestel, M. L. L. Prevoo, M. A. van’t Hof, M. H. van Rijswijk, L. B. A. van de Putte, and P. L. C. M. van Riel, “Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis,” Arthritis & Rheumatism, vol. 39, no. 1, pp. 34–40, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. F. A. Kurreeman, L. Padyukov, R. B. Marques et al., “A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis,” PLoS Medicine, vol. 4, no. 9, article e278, 2007. View at Publisher · View at Google Scholar
  39. M. Rothe, S. C. Wong, W. J. Henzel, and D. V. Goeddel, “A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor,” Cell, vol. 78, no. 4, pp. 681–692, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Wang, J. Kristan, L. Hao, C. S. Lenkoski, Y. Shen, and L. A. Matis, “A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis,” Journal of Immunology, vol. 164, no. 8, pp. 4340–4347, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Cui, E. A. Stahl, S. Saevarsdottir et al., “Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis,” PLoS Genetics, vol. 9, no. 3, Article ID e1003394, 2013. View at Publisher · View at Google Scholar · View at Scopus